التفاصيل البيبلوغرافية
| العنوان: |
Safety and Efficacy of Repeat Administration of Triamcinolone Acetonide Extended-release in Osteoarthritis of the Knee: A Phase 3b, Open-label Study. |
| المؤلفون: |
Spitzer, Andrew I., Richmond, John C., Kraus, Virginia B., Gomoll, Andreas, Jones, Deryk G., Huffman, Kim M., Peterfy, Charles, Cinar, Amy, Lufkin, Joelle, Kelley, Scott D. |
| المصدر: |
Rheumatology & Therapy; Mar2019, Vol. 6 Issue 1, p109-124, 16p |
| مصطلحات موضوعية: |
OSTEOARTHRITIS, TRIAMCINOLONE acetonide, INTRA-articular injections, INJECTION wells, PAIN measurement |
| مصطلحات جغرافية: |
ONTARIO |
| مستخلص: |
Introduction: The aim of this work is to assess the safety and efficacy of repeat administration of triamcinolone acetonide extended-release (TA-ER) in patients with symptomatic knee osteoarthritis (OA), including those with advanced radiographic severity.Methods: In this phase 3b, single-arm, open-label study, patients aged ≥ 40 years received the first intra-articular TA-ER injection on day 1. Patients received the second injection timed to the response to the first injection (at either week 12, 16, 20, or 24). Patients who received two injections were evaluated every 4 weeks for 52 weeks. Safety was evaluated via treatment-emergent adverse events and any change at 52 weeks in index-knee radiographs (chondrolysis, osteonecrosis, insufficiency fractures, subchondral bone changes). Exploratory efficacy endpoints included Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)-A (pain), -B (stiffness), -C (function), and Knee Injury and Osteoarthritis Outcome Score-Quality of Life (KOOS-QoL) after each injection. Initiative in Methods, Measurements and Pain Assessment in Clinical Trials (IMMPACT) criteria were used to determine moderate and substantial treatment response.Results: A total of 208 patients were enrolled and received the first injection of TA-ER; 179 (86.1%) received the second injection (median time to second injection: 16.6 weeks). Both injections were well tolerated, with no unexpected adverse events or significant radiographic changes at week 52. The magnitude and duration of clinical benefit after the first and second injections were similar, and most patients reported a substantial (≥ 50%) analgesic response after both doses.Conclusions: Repeat administration of TA-ER using a flexible dosing schedule timed to patient response was well tolerated, with no radiographic evidence of cartilage impact. Both injections resulted in similar improvements in OA symptoms across a broad spectrum of disease severity reflective of that seen in clinical practice.Trial Registration Information: ClinicalTrials.gov identifier: NCT03046446.Funding: Flexion Therapeutics, Inc.Plain Language Summary: Plain language summary available for this article. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology & Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder